Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP?
Rattachement africain : us, nz. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Long-acting injectable pre-exposure prophylaxis (PrEP) is the most promising biomedical HIV prevention innovation since the release of oral PrEP in 2012, but its reach may be undermined by inadequate access. The high list price of injectable PrEP has been cited as a critical driver of access issues for cabotegravir-formulated injectable PrEP, challenges that are likely to persist for the recently approved, twice-yearly injectable PrEP drug, lenacapavir. In this Viewpoint piece, we argue that now is the time to take stock of our recent progress with the rollout of injectable cabotegravir to learn from our mistakes for lenacapavir for PrEP. SETTING: An online, US national cohort study of sexual and gender minority individuals that are vulnerable to HIV. METHODS: We report preliminary longitudinal data (2022-2025) on interest in and uptake of long-acting injectable cabotegravir. RESULTS: During their first assessment, 61% reported that they were either "somewhat interested" or "very interested" in bimonthly injectable PrEP. However, by their 12-month assessment, only 42 individuals had taken up injectable PrEP, and at their 24-month assessment 57 individuals were on injectable PrEP. Participants reported several challenges when beginning and maintaining access to injectable PrEP, including challenges at the provider and clinic-level, and regarding insurance coverage and payment/cost issues. CONCLUSIONS: Emerging data suggest high interest in injectable PrEP but low uptake, with some participants reporting challenges obtaining insurance coverage, alongside other clinic-level barriers. It is our hope that assessments of current and persisting barriers to cabotegravir can offer preliminary but critical insights for the rollout of lenacapavir.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP?
- Date Crossref
- 01/04/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Albert Einstein College of Medicine Montefiore Health System pays non établi dans la noticeUniversité ou école supérieure
-
Montefiore Health System pays non établi dans la noticeÉtablissement de santé
-
Florida International University Department of Health Promotion pays non établi dans la noticeUniversité ou école supérieure
-
Health Promotion Agency pays non établi dans la noticeInstitution
-
The Graduate Center pays non établi dans la noticeUniversité ou école supérieure
-
CUNY Graduate School of Public Health and Health Policy Department of Community Health and Social Sciences pays non établi dans la noticeUniversité ou école supérieure
-
CUNY Institute for Implementation Science in Population Health pays non établi dans la noticeStructure de recherche
Montefiore Health System — Albert Einstein College of Medicine, Montefiore Health System et Department of Health Promotion — Florida International University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.